ARROWHEAD PHARMACEUT

ARWR
Delayed Quote. Delayed  - 01/22 04:00:00 pm
82.07USD +2.56%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Number of employees : 232 people.
Sales per Business
20192020
USD
(in Million)
%USD
(in Million)
%
Innovative Drugs 168.80100% 87.99100%
Sales per region
20192020
USD
(in Million)
%USD
(in Million)
%
United States 168.80100% 87.99100%
Managers
Name Title
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Kenneth Allen Myszkowski Chief Financial Officer
Javier San Martin Chief Medical Officer
Jeff Ketelhut Vice President-Information Technology & Systems
Mauro Ferrari Independent Director
Michael S. Perry Lead Independent Director
William D. Waddill Independent Non-Executive Director
Marianne de Backer Independent Director
Adeoye Y. Olukotun Independent Director
Shareholders
Name Equities %
The Vanguard Group, Inc. 8,816,540 8.58%
OppenheimerFunds, Inc. 7,803,131 7.59%
SSgA Funds Management, Inc. 4,543,124 4.42%
BlackRock Fund Advisors 3,506,774 3.41%
Christopher Anzalone 3,344,022 3.25%
Johnson & Johnson Innovation JJDC, Inc. 3,260,869 3.17%
Invesco Advisers, Inc. 3,000,000 2.92%
Bridger Management LLC 2,976,183 2.90%
QVT Financial LP 2,556,256 2.49%
Prescott Group Capital Management LLC 1,909,330 1.86%
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
ARROWHEAD PHARMACEUTICALS, INC.6.96%8 433
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
REGENERON PHARMACEUTICALS11.32%56 760
BEIGENE, LTD.44.94%34 148
GENMAB A/S7.31%28 292
BIONTECH SE33.02%26 111
ARGENX SE5.21%14 672
HUALAN BIOLOGICAL ENGINEERING INC.21.69%14 468
MYOKARDIA, INC.0.00%11 993
NEUROCRINE BIOSCIENCES, INC.19.98%10 923
MIRATI THERAPEUTICS, INC.-2.36%10 783
DENALI THERAPEUTICS INC.-5.53%9 489
ULTRAGENYX PHARMACEUTICAL INC.1.47%9 293
FATE THERAPEUTICS, INC.6.88%8 909
ASCENDIS PHARMA A/S-3.67%8 677
KODIAK SCIENCES INC.11.86%8 277
SAREPTA THERAPEUTICS, INC.-42.38%7 752
ACCELERON PHARMA INC.-2.60%7 508
PEPTIDREAM INC.11.26%7 062